Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122i mutations and wild-type transthyretin transthyretin cardiac amyloid study (TRACS)

Circulation: Heart Failure

Volumn 4, Issue 2, 2011, Pages 121-128

  Bhuiyan, Taslima ^a   Helmke, Stephen ^a   Patel, Ayan R ^b   Ruberg, Frederick L ^c   Packman, Jeff ^d   Cheung, Kin ^d   Grogan, Donna ^d   Maurer, Mathew S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FoldRx Pharmaceuticals Inc   (United States)

Author keywords

Amyloid; Heart failure; Pressure volume relations; Transthyretin

Indexed keywords

PREALBUMIN;

ARTICLE; CLINICAL ARTICLE; DOPPLER ECHOCARDIOGRAPHY; FOLLOW UP; HAZARD RATIO; HEART AMYLOIDOSIS; HEART TRANSPLANTATION; HEART VENTRICLE PRESSURE; HEART VENTRICLE VOLUME; HUMAN; MORTALITY; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; TWO DIMENSIONAL ECHOCARDIOGRAPHY; AGED; AMYLOIDOSIS; BIOPSY; CARDIOMYOPATHY; CLINICAL TRIAL; FEMALE; GENETIC PREDISPOSITION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; KAPLAN MEIER METHOD; MALE; METABOLISM; MULTICENTER STUDY; MUTATION; PATHOPHYSIOLOGY; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; UNITED STATES;

AGED; AGED, 80 AND OVER; AMYLOIDOSIS; BIOPSY; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MUTATION; PHENOTYPE; PREALBUMIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; TIME FACTORS; UNITED STATES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 79955931832     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.910455     Document Type: Article

References (39)

1. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047-2060. (Pubitemid 41377426)
2. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: A comparison with light chainassociated amyloidosis. Arch Intern Med. 2005;165:1425-1429. (Pubitemid 40973426)
3. Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: Evidence for a late-onset disease of genetic etiology. Am J Hum Genet. 1990;47: 127-136.
4. Enqvist S, Peng S, Persson A, Westermark P. Senile amyloidoses- diseases of increasing importance. Acta Histochem. 2003;105:377-378.
5. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997; 336:466-473. (Pubitemid 27074357)
6. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Ann Med. 2008;40:232-239. (Pubitemid 351482541)
7. Connors LH, Prokaeva T, Lim A, Théberge R, Falk RH, Doros G, Berg A, Costello CE, O'Hara C, Seldin DC, Skinner M. Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158:607-614.
8. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi- Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S. Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. Circulation. 2009;120:1203-1212.
9. Klein AL, Hatle LK, Taliercio CP, Oh JK, Kyle RA, Gertz MA, Bailey KR, Seward JB, Tajik AJ. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation. 1991;83:808-816.
10. Sallach JA, Klein AL. Tissue Doppler imaging in the evaluation of patients with cardiac amyloidosis. Curr Opin Cardiol. 2004;19:464-471. (Pubitemid 39222962)
11. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107:2446-2452. (Pubitemid 36605227)
12. Koyama J, Ray-Sequin PA, Falk RH. Prognostic significance of ultrasound myocardial tissue characterization in patients with cardiac amyloidosis. Circulation. 2002;106:556-561. (Pubitemid 34827704)
13. Klotz S, Hay I, Dickstein ML, Yi GH, Wang J, Maurer MS, Kass DA, Burkhoff D. Single-beat estimation of end-diastolic pressure-volume relationship: A novel method with potential for noninvasive application. Am J Physiol Heart Circ Physiol. 2006;291:H403-H412.
14. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319-328. (Pubitemid 41098849)
15. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, et al. Recommendations for quantitation of the left ventricle by twodimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two- Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2: 358-367.
16. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;57:450-458. (Pubitemid 16119719)
17. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982-1990. (Pubitemid 46625948)
18. Kelly RP, Ting CT, Yang TM, Liu CP, Maughan WL, Chang MS, Kass DA. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 1992;86:513-521.
19. Maurer MS S-BJ, El-Khoury Rumbarger L, Yushak M, King DL, Burkhoff D. Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure. Circ Heart Fail. 2009;2:189-196.
20. Suga H, Goto Y, Futaki S, Kawaguchi O, Yaku H, Hata K, Takasago T. Systolic pressure-volume area (PVA) as the energy of contraction in Starling's law of the heart. Heart Vessels. 1991;6:65-70.
21. Todaka K, Wang J, Yi GH, Knecht M, Stennett R, Packer M, Burkhoff D. Impact of exercise training on ventricular properties in a canine model of congestive heart failure. Am J Physiol. 1997;272:H1382-H1390.
22. Pages RA, Robbins J, Edelhoch H. Binding of thyroxine and thyroxine analogs to human serum prealbumin. Biochemistry. 1973;12:2773-2779.
23. Saraiva MJ. Transthyretin mutations in health and disease. Hum Mutat. 1995;5:191-196.
24. Quintas A, Saraiva MJ, Brito RM. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J Biol Chem. 1999;274:32943-32949. (Pubitemid 129535333)
25. Hammarstrom P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A. 2002;99(suppl 4):16427-16432. (Pubitemid 35470989)
26. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95:535-537. (Pubitemid 40247559)
27. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299:713-716. (Pubitemid 36159487)
28. Kelly JW. Mechanisms of amyloidogenesis. Nat Struct Biol. 2000;7: 824-826.
29. Saraiva MJ. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat. 2001;17:493-503. (Pubitemid 32480084)
30. Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, Thibodeau SN. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med. 1996;101:395-400. (Pubitemid 26392857)
31. Sunagawa K, Maughan WL, Burkhoff D, Sagawa K. Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol. 1983;245:H773-H780. (Pubitemid 14245481)
32. Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, Offord KP, Greipp PR, Edwards WD, Tajik AJ. Echocardiographic findings in systemic amyloidosis: Spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6:737-743. (Pubitemid 16247618)
33. Ogiwara F, Koyama J, Ikeda S, Kinoshita O, Falk RH. Comparison of the strain Doppler echocardiographic features of familial amyloid polyneuropathy (FAP) and light-chain amyloidosis. Am J Cardiol. 2005;95: 538-540. (Pubitemid 40247560)
34. Patel AR, Dubrey SW, Mendes LA, Skinner M, Cupples A, Falk RH, Davidoff R. Right ventricular dilation in primary amyloidosis: An independent predictor of survival. Am J Cardiol. 1997;80:486-492. (Pubitemid 27371756)
35. Tei C, Dujardin KS, Hodge DO, Kyle RA, Tajik AJ, Seward JB. Doppler index combining systolic and diastolic myocardial performance: Clinical value in cardiac amyloidosis. J Am Coll Cardiol. 1996;28:658-664. (Pubitemid 26288647)
36. Kristen AV, Meyer FJ, Perz JB, Schonland SO, Hundemer M, Hegenbart U, Singer R, Schnabel PA, Sack FU, Goldschmidt H, Katus HA, Dengler TJ. Risk stratification in cardiac amyloidosis: Novel approaches. Transplantation. 2005;80:S151-155. (Pubitemid 41552928)
37. Kristen AV, Perz JB, Schonland SO, Hansen A, Hegenbart U, Sack FU, Goldschmidt H, Katus HA, Dengler TJ. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant. 2007;26:1 313-1 319. (Pubitemid 350256989)
38. Kristen AV, Perz JB, Schonland SO, Hegenbart U, Schnabel PA, Kristen JH, Goldschmidt H, Katus HA, Dengler TJ. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 2007; 9:617-624. (Pubitemid 46702816)
39. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des. 2008;14: 3 219-3 230